Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation

NEXT STORY
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
PREV STORY
Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2021

author_avatar
NASDAQ Market News

Exosomes Market Research Report by Product, by Treatment, by Workflow, by End-User, by Application, by Region – Global Forecast to 2026 – Cumulative Impact of COVID-19

author_avatar
NASDAQ Market News

Antibiotics: The Quest for New Super Drugs: Technologies, Markets, Competitors and Opportunities Report: 2017-2022 Analysis and Forecasts

Dublin, July 13, 2017 (GLOBE NEWSWIRE) -- The "Antibiotics: the Quest for New Super ...

author_avatar
NASDAQ Market News